153 related articles for article (PubMed ID: 16356876)
1. Chlormadinone acetate (CMA) in oral contraception--a new opportunity.
Bouchard P
Eur J Contracept Reprod Health Care; 2005; 10 Suppl 1():7-11. PubMed ID: 16356876
[TBL] [Abstract][Full Text] [Related]
2. Profile of the progesterone derivative chlormadinone acetate - pharmocodynamic properties and therapeutic applications.
Druckmann R
Contraception; 2009 Apr; 79(4):272-81. PubMed ID: 19272496
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of chlormadinone acetate following single and multiple oral dosing of chlormadinone acetate (2 mg) and ethinylestradiol (0.03 mg) and elimination and clearance of a single dose of radiolabeled chlormadinone acetate.
Terlinden R; Uragg H; Göhler K; Kneip C
Contraception; 2006 Sep; 74(3):239-44. PubMed ID: 16904418
[TBL] [Abstract][Full Text] [Related]
4. Progestogens with antiandrogenic properties.
Raudrant D; Rabe T
Drugs; 2003; 63(5):463-92. PubMed ID: 12600226
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled Phase III trial.
Plewig G; Cunliffe WJ; Binder N; Höschen K
Contraception; 2009 Jul; 80(1):25-33. PubMed ID: 19501212
[TBL] [Abstract][Full Text] [Related]
6. Comparative effects of chlormadinone acetate and its 3alpha- and 3beta-hydroxy metabolites on progesterone, androgen and glucocorticoid receptors.
Schneider J; Kneip C; Jahnel U
Pharmacology; 2009; 84(2):74-81. PubMed ID: 19590256
[TBL] [Abstract][Full Text] [Related]
7. At 10 years of chlormadinone use in Latin America: a review.
Barriga P P; Ambrosi Penazzo N; Franco Finotti M; Celis AA; Cerdas O; Chávez JA; Cuitiño LA; Fernandes CE; Plata MA; Tirán-Saucedo J; Vanhauwaert PS
Gynecol Endocrinol; 2016 Jul; 32(7):517-20. PubMed ID: 27113551
[TBL] [Abstract][Full Text] [Related]
8. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
9. Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study.
Schramm G; Heckes B
Contraception; 2007 Aug; 76(2):84-90. PubMed ID: 17656175
[TBL] [Abstract][Full Text] [Related]
10. Quality of sexual life in hyperandrogenic women treated with an oral contraceptive containing chlormadinone acetate.
Caruso S; Rugolo S; Agnello C; Romano M; Cianci A
J Sex Med; 2009 Dec; 6(12):3376-84. PubMed ID: 19832931
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effects of chlormadinone acetate-pellet implantation and orchidectomy on benign prostatic hypertrophy in the dog.
Kawakami E; Tsutsui T; Shimizu M; Orima H; Fujita M; Ogasa A
Int J Androl; 1995 Oct; 18(5):248-55. PubMed ID: 8567095
[TBL] [Abstract][Full Text] [Related]
12. Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon).
Worret I; Arp W; Zahradnik HP; Andreas JO; Binder N
Dermatology; 2001; 203(1):38-44. PubMed ID: 11549798
[TBL] [Abstract][Full Text] [Related]
13. Effects of an oral contraceptive containing chlormadinone and ethinylestradiol on acne-prone skin of women of different age groups: an open-label, single-centre, phase IV study.
Kerscher M; Reuther T; Bayrhammer J; Schramm G
Clin Drug Investig; 2008; 28(11):703-11. PubMed ID: 18840013
[TBL] [Abstract][Full Text] [Related]
14. Selective effect of chlormadinone acetate on brain allopregnanolone and opioids content.
Pluchino N; Lenzi E; Merlini S; Giannini A; Cubeddu A; Casarosa E; Begliuomini S; Luisi M; Cela V; Genazzani AR
Contraception; 2009 Jul; 80(1):53-62. PubMed ID: 19501216
[TBL] [Abstract][Full Text] [Related]
15. The effects of two monophasic oral contraceptives containing 30 mcg of ethinyl estradiol and either 2 mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters.
Winkler UH; Sudik R
Contraception; 2009 Jan; 79(1):15-23. PubMed ID: 19041436
[TBL] [Abstract][Full Text] [Related]
16. Oral progestogen versus intramuscular progesterone for luteal support after assisted reproductive technology treatment: a prospective randomized study.
Iwase A; Ando H; Toda S; Ishimatsu S; Harata T; Kurotsuchi S; Shimomura Y; Goto M; Kikkawa F
Arch Gynecol Obstet; 2008 Apr; 277(4):319-24. PubMed ID: 17938943
[TBL] [Abstract][Full Text] [Related]
17. Evidence that in healthy young women, a six-cycle treatment with oral contraceptive containing 30 mcg of ethinylestradiol plus 2 mg of chlormadinone acetate reduces fat mass.
Uras R; Orrù M; Etzi R; Peppi G; Marotto MF; Pilloni M; Zedda P; Lello S; Melis GB; Paoletti AM
Contraception; 2009 Feb; 79(2):117-21. PubMed ID: 19135568
[TBL] [Abstract][Full Text] [Related]
18. Relationship between prostatic atrophy and apoptosis in the canine spontaneous benign prostatic hyperplasia (BPH) following chlormadinone acetate (CMA).
Murakoshi M; Ikeda R; Fukui N; Nakayama T
Tokai J Exp Clin Med; 2001 Jul; 26(2):71-5. PubMed ID: 11806444
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles)--an open-label, prospective, noncontrolled, office-based Phase III study.
Zahradnik HP; Hanjalic-Beck A
Contraception; 2008 May; 77(5):337-43. PubMed ID: 18402849
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical studies in canine prostatic hyperplasia--effect of antiandrogen.
Murakoshi M; Ikeda R; Tagawa M; Nakayama T
Tokai J Exp Clin Med; 1999 Jun; 24(2):77-83. PubMed ID: 10641996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
